Alkeon Capital Management
ORIC icon

Alkeon Capital Management’s Oric Pharmaceuticals ORIC Stock Holding History

Alkeon Capital Management’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40.5M Sell
3,739,096
-765,000
-17% -$6.94M 0.05% 92
2026
Q1 		$57.1M Hold
4,504,096
– – 0.1% 77
2025
Q4 		$36.8M Hold
4,504,096
– – 0.06% 96
2025
Q3 		$54M Hold
4,504,096
– – 0.08% 80
2025
Q2 		$45.7M Buy
4,504,096
+500,000
+12% +$3.36M 0.08% 80
2025
Q1 		$22.3M Buy
4,004,096
+100,000
+3% +$874K 0.05% 91
2024
Q4 		$31.5M Hold
3,904,096
– – 0.06% 79
2024
Q3 		$40M Buy
3,904,096
+100,000
+3% +$989K 0.07% 78
2024
Q2 		$26.9M Buy
3,804,096
+100,000
+3% +$895K 0.04% 89
2024
Q1 		$50.9M Buy
3,704,096
+100,000
+3% +$1.19M 0.09% 79
2023
Q4 		$33.2M Buy
3,604,096
+124,807
+4% +$902K 0.07% 81
2023
Q3 		$21M Buy
3,479,289
+500,000
+17% +$4.1M 0.04% 86
2023
Q2 		$23.1M Buy
2,979,289
+580,037
+24% +$3.29M 0.04% 94
2023
Q1 		$13.7M Hold
2,399,252
– – 0.03% 108
2022
Q4 		$14.1M Buy
2,399,252
+292,284
+14% +$987K 0.05% 112
2022
Q3 		$6.74M Hold
2,106,968
– – 0.02% 127
2022
Q2 		$9.44M Buy
2,106,968
+200,000
+10% +$798K 0.03% 125
2022
Q1 		$10.2M Buy
1,906,968
+480,000
+34% +$4.32M 0.02% 132
2021
Q4 		$21M Buy
1,426,968
+429,979
+43% +$6.7M 0.04% 123
2021
Q3 		$20.8M Hold
996,989
– – 0.04% 133
2021
Q2 		$17.6M Sell
996,989
-1,072
-0.1% -$23.5K 0.03% 148
2021
Q1 		$24.5M Buy
998,061
+100,000
+11% +$3.16M 0.04% 132
2020
Q4 		$30.4M Buy
898,061
+595,000
+196% +$17.1M 0.05% 126
2020
Q3 		$7.58M Buy
+303,061
New +$7.21M 0.01% 132

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Alkeon Capital Management's ORIC Position: Q2 2026 in Review

Alkeon Capital Management reduced its Oric Pharmaceuticals (ORIC) stake by 17% in Q2 2026, selling an estimated $6.94M and leaving 3,739,096 shares worth $40.5M. The position accounts for 0.05% of the portfolio, ranked #92.

Alkeon Capital Management first reported a position in ORIC in Q3 2020 and has held it in 24 quarters since. The position peaked at $57.1M in Q1 2026. 181 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Alkeon Capital Management held 3,739,096 shares of Oric Pharmaceuticals worth $40.5M as of Q2 2026.
  • Alkeon Capital Management sold 765,000 Oric Pharmaceuticals shares in Q2 2026, an estimated $6.94M.
  • Oric Pharmaceuticals made up 0.05% of Alkeon Capital Management's portfolio in Q2 2026, its #92 holding.
  • Alkeon Capital Management first reported a position in Oric Pharmaceuticals in Q3 2020 and has held it in 24 quarters since.
  • Alkeon Capital Management's Oric Pharmaceuticals position peaked at $57.1M in Q1 2026.
  • 181 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Alkeon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.